TherapeuticsMD (TXMD) Tops Q3 EPS by 1c

TherapeuticsMD (NYSE: TXMD) reported Q3 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $5.19 million versus the consensus estimate of $5.01 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins